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Introduction: Blast-related head injuries are among the most prevalent injuries suffered by
military personnel deployed in combat and mild traumatic brain injury (mTBI) or concussion
on the battlefield in Iraq/Afghanistan has resulted in its designation as a “signature injury.”
Vestibular complaints are the most frequent sequelae of mTBI, and vestibular rehabilita-
tion (VR) has been established as the most important treatment modality for this group of
patients.
Materials and Methods: We studied the effectiveness of a novel brain and VR treatment
post-traumatic stress disorder (PTSD) in subjects who had suffered combat-related trau-
matic brain injuries in terms of PTSD symptom reduction. The trial was registered as Clin-
icalTrials.gov Identifier: NCT02003352. (http://clinicaltrials.gov/ct2/show/NCT02003352?
term=carrick&rank=6). We analyzed the difference in the Clinician Administered DSM-IV
PTSD Scale (CAPS) scores pre- and post-treatment using our subjects as their own matched
controls. The study population consisted of 98 combat veterans maintaining an alpha of
<0.05 and power of 80%.
Results: Prior to treatment, 75 subjects representing 76.53 % of the sample were classi-
fied in the 2 most severe categories of PTSD. Forty-one subjects, representing 41.80 % of
the total sample, were classified in the extreme category of PTSD and 34 subjects, repre-
senting 34.70 % of the total sample, were classified in the severe category of PTSD. After
treatment, we observed a large reduction in CAPS severity scores with both statistical and
substantive significance.
Discussion: Treatment of PTSD as a physical injury rather than a psychiatric disorder is
associated with strong statistical and substantive significant outcomes associated with
a decrease of PTSD classification. The stigma associated with neuropsychiatric disorders
may be lessened when PTSD is treated with brain and VR with a potential decrease in
suffering of patients, family, and society.
Keywords: PTSD, vestibular rehabilitation, off vertical axis rotation, DSM-IV CAPS, brain
INTRODUCTION
Blast-related head injuries are among the most prevalent injuries
suffered by military personnel deployed in combat (1) and mild
traumatic brain injury (mTBI) or concussion on the battlefield
in Iraq/Afghanistan has resulted in its designation as a “signa-
ture injury” (2). Blast-related mTBI appears to increase the risk
of post-traumatic stress disorder (PTSD) with a substantial over-
lap between mTBI and PTSD issues (3, 4). Military deployments
to Afghanistan and Iraq have been associated with an elevated
prevalence of both PTSD and mTBI among combat veterans (5–7)
The diagnosis and management of PTSD when a comorbid mTBI
may also exist presents a challenge to interdisciplinary care teams
at the Department of Veterans Affairs (VA) and civilian medical
facilities, particularly when the patient reports a history of blast
exposure (8). From a treatment perspective, trauma-focused cog-
nitive behavioral therapy (TF-CBT) is the therapy that is associated
with superior improvement in PTSD symptoms and psychosocial
outcome in mTBI survivors (9) with a slight advantage compared
to all other treatments (10). Vestibular complaints are the most
frequent sequelae of mTBI, and vestibular rehabilitation (VR) has
been established as the most important treatment modality for
this group of patients (11). However, we could find no published
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case study reports or randomized controlled trials specific to VR
in veterans who have PTSD after mTBI. Traumatic brain injury
(TBI) caused by blast injury explosives used in modern warfare
has become a common injury for troops, yet there is a paucity
of neuropathology studies investigating the effects of high explo-
sives on the human brain. There are, however, many studies that
have demonstrated that athletes with repeated head trauma can
develop a chronic traumatic encephalopathy (CTE), a neurode-
generative disease with similar clinical features to wartime blast
injury (12). Our team has extensive experience in the treatment
of mTBI and CTE in combat veterans, professional athletes, and
Olympians using a novel VR. The PTSD Guideline Development
Group and the National Collaborating Center for Mental Health
review team has developed a guideline (NICE) based on best avail-
able evidence to advise on the treatment and management of
post-traumatic stress disorder (PTSD) (13). NICE recommended
three treatments [selective serotonin re-uptake inhibitors (SSRI),
eye movement desensitization and reprocessing (EMDR) and TF-
CBT] and a meta-analysis revealed that TF-CBT is most effective
and associated with the best outcome (10, 14, 15). The reduction in
PTSD symptoms is positively associated with a reduction in post-
concussive symptoms suggesting that PTSD and mTBI symptoms
are interdependent and mutually influence one another (16). Bal-
ance impairment, or postural instability, is a common source of
residual physical disability after severe TBI (17) that is best treated
with VR. Explosive blast TBI is one of the more serious wounds
suffered by United States service members injured in the current
conflicts in Iraq and Afghanistan (18) and there is limited research
that demonstrates effective treatment outcomes when compared
to the sports medicine literature of similar injuries. This investiga-
tion has the potential to change the treatment of PTSD after mTBI
resulting in changed and saved lives of our service personnel and
their families.
MATERIALS AND METHODS
RESEARCH AIMS AND HYPOTHESIS
Research question
The specific aim of this study was to study the effectiveness in terms
of PTSD symptom reduction of a novel brain and VR treatment
modality in patients with PTSD who have suffered combat-related
traumatic brain injuries.
Hypothesis
Given the similarities in clinical features between CTE and blast-
related mTBI, we hypothesized that VR treatment modalities will
be effective in PTSD symptom reduction.
PRELIMINARY DATA
We searched a variety of databases for randomized controlled tri-
als of mTBI and PTSD and VR up until September 2013 without
success. Our search included Cochrane Injuries Group’s special-
ized register, Cochrane Depression, Anxiety and Neurosis Group’s
specialized register, Cochrane Central Register of Controlled Tri-
als, MEDLINE, PsycINFO, EMBASE, CINAHL, AMED, ERIC, and
PsycBITE. We assembled an established clinical team of specialists,
internationally known in the diagnosis and treatment of mTBI and
PTSD to participate in this study. The 2008 Institute of Medicine
review of interventions research for post-traumatic stress disor-
der (PTSD) concluded that new, well-designed studies are needed
to evaluate the efficacy of treatments for PTSD (19). We had the
funding and patient population to conduct and complete the study
that will act as an initial pilot project. TBI may reflect an overlap
between brain regions vulnerable to TBI, and the neural circuitry
of these disorders (20).
RESEARCH DESIGN AND METHODS
The study was approved by our Institutional IRB and conducted in
accordance with the principles of the Declaration of Helsinki. The
trial was registered with a service of the U.S. National Institutes of
Health as ClinicalTrials.gov Identifier: NCT02003352. There was
equipoise.
STUDY DESIGN
This before–after intervention trial was designed to identify the
effectiveness of a novel brain and VR treatment modality in
patients with PTSD who have suffered combat related traumatic
brain injuries. Subjects served as their own matched controls. We
accomplished the specific aim of our study by analyzing the differ-
ence in the Clinician Administered DSM-IV PTSD Scale (CAPS)
scores (21) pre- and post-treatment in our subjects as outcomes to
compare the effectiveness of the interventions. The CAPS is con-
sidered to be the gold standard for diagnosing PTSD and assessing
symptom severity (21, 22). We expected differences in the out-
comes after treatment to demonstrate a positive change that would
be immediate and at follow-up over time, i.e., 3 months after cessa-
tion of a 2-week treatment period. All CAPS testing was conducted
by one qualified licensed psychologist who was blinded to all com-
ponents of the study. The study design included one pre-treatment
assessment and two post-treatment assessments (at 1 week and
3 months). The study was performed at the department of Neurol-
ogy of our Institutional Brain Center in Dallas, TX, USA. Patient
recruitment began after IRB approval and study registration in
October, 2013.
SAMPLE SIZE
Our sample size calculations were based on expected differences in
CAPS scores at follow-up. There is,however, a paucity of data in the
literature specific to power and sample calculations over the long
term. There are two quality randomized controlled studies that
compared DSMIV CAPS score changes as outcome measures. One
study looked at paroxetine therapy and the other TF-CBT. These
studies demonstrated a total CAPS score of 34.8 points (SD= 25.7)
in the paroxetine group (23) and 23.7 (SD= 26.1) in the cognitive
behavioral group (24). There are no studies that measure changes
in CAPS scores after VR. We estimated that the VR group in our
study would have at least a comparable outcome to the paroxetine
group. The power calculations demonstrated that a total of 89 par-
ticipants were needed to demonstrate a difference of 11.1 points
(alpha= 5%, power= 80%). A difference of 0.50 SD represents a
decrease in CAPS scores of approximately 10 points. We felt that an
effect size (ES) of d = 0.50 would represent a clinically significant
effect. The estimated sample size for the Cox PH regression Wald
test, log-hazard metric in a 2-group comparison demonstrated
that 66 subjects would be needed. Further, the estimated sample
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sizes for two-sample comparison of survivor functions using the
Log-rank test, Freedman method with an alpha of 0.05 (two sided)
and a hazard ratio of 0.50 and 80% power demonstrated that we
needed a total of 72 subjects. All of these sample size calculations
were similar and we therefore decided that 82 subjects would be
needed in total. To allow for a 20% attrition rate at follow up, we
added an additional 16 subjects to the study for a total of 98 sub-
jects. This study design maintained a Type I error at an acceptable
level of 0.05 in order to minimize the risk of false positive findings.
PARTICIPANTS
The study population consisted of 98 combat veterans who had
suffered a TBI with PTSD, referred to our study by Veteran’s
groups. All subjects were male with a mean age of 39 years with a
minimum age of 20 years and a maximum age of 60 years. They
all met the inclusion requirements and did not have any of the
exclusion requirements.
INCLUSION CRITERIA
Military combat veterans who had suffered a TBI and post-
traumatic stress disorder (PTSD) that were exposed to war-zone
events in operation enduring freedom (OEF) and/or operation
Iraqi freedom (OIF). Subjects fulfilled all criteria for a diagnosis
of chronic PTSD based on the DSM-IV (25) with qualifying scores
on the CAPS (21). All subjects must have had previous treatments
for PTSD that were not successful. Subjects were 18 years of age or
older and were able to give written informed consent.
EXCLUSION CRITERIA
Presence of any of the following DSM-IV diagnoses: psychotic
disorder, mania or bipolar disorder; current major depression
with psychotic features; current drug or alcohol or substance/drug
dependence; patients who are considered a suicidal risk.
ASSESSMENTS AND OUTCOME MEASURES
We used changes in the DSM-IV CAPS scores before and after
treatment to distinguish between the estimated frequency and
intensity of the various symptoms. Frequency and intensity scores
were combined to give a total CAPS score (range: 0–136) as stan-
dard in the DSM-IV CAPS evaluation procedures (21, 22). CAPS
testing was scheduled pre-intervention, 1 week post-intervention,
and at 3 months post-intervention.
INTERVENTION: BRAIN AND VESTIBULAR REHABILITATION
Each subject was treated with strategies central to gaze stabiliza-
tion with head movements and activation of the vestibular–ocular
response, off axis whole body rotation, visual pursuit, and visual
saccadic eye movements to novel targets [well described in Ref.
(26–30)]. However, because our clinical experience has shown that
customized treatment based on reported symptoms and finding
of physical and neurological examination by trained clinicians is
more effective than standard VR treatment modalities in athletes
suffering repeated concussions, each subject received a custom
treatment plan. This allowed the doctor to tailor the treatment and
maximize its effect. For example, one subject might have a deficit
of gaze holding in right gaze and another in left gaze. Both would
have gaze holding strategies prescribed specific to their clinical
needs. To avoid inter-rater variability, the same clinician decided
the treatment plan for all subjects. Each subject received daily ses-
sions of three VR treatment modalities for 2 weeks (5 week days
per week with 2 weekend days off). Subjects were instructed to
rest between treatments. No medication changes were prescribed
during the treatment period. The treatment was administered by
clinicians certified in VR. These clinicians did not know the results
of the CAPS pre-treatment evaluation.
PROCEDURE
All subjects met the inclusion criterion at the referring agency and
then underwent a comprehensive medical history and neurologi-
cal examination as well as a CAPS test to confirm PTSD after mTBI.
They were carefully examined to ensure that they did not meet any
of the exclusion criteria. The subjects that were acceptable to the
study were given a detailed explanation of the study and an offer
to participate in the study after giving informed consent. Partic-
ipants underwent another CAPS test 1 week after their treatment
had been finished and were scheduled again at 3 months.
STATISTICAL ANALYSES
A statistical analysis was conducted using Stata/SE 13.1 (Stata-
Corp, College Station, TX, USA) according to an intention-to-treat
(ITT) approach. Since it was expected that some participants
might not complete the study for a variety of reasons, the analy-
sis procedure included provisions for identifying these individuals
making a careful note of the reasons for no completion if possible.
However, compliance with treatment appointments was neces-
sary for the subject to be included in the analysis. An individual
who missed more than 25% of their treatment appointments
would be categorized as being non-compliant. Dropouts were to
be identified separately from those individuals who were deemed
non-compliant. The short-term efficacy of the treatment modal-
ity was evaluated by considering the difference pre and post (at
1 week after treatment) of the CAPS Total Severity Scores for each
subject (matched pairs) and by calculating the probability of error
(p value) by a two-tailed t -Test for repeated measures maintaining
an alpha of<0.05. The ES was calculated in three ways to ascertain
if the difference between the matched pairs was both statistically
and clinically significant: as proposed by Cohen, the ratio of the
mean difference between the two groups (pre and 1 week post)
divided by the pooled variance of the groups was calculated (31)
Another ES as proposed by Hedges was calculated using a formula
similar to Cohen’s but calculating the SD using N − 1 instead of
N (where N is the number of samples considered) (32). In both
cases, an ES value of 0.2 represents a small statistical and clinical
difference between two groups; an ES value of 0.5 represents a
moderate difference; and an ES value of 0.8 represents a large dif-
ference (31). Finally, the ES was obtained by calculating the point
biserial correlation: a percent improvement between CAPS Total
Severity Score was calculated [(post-test group mean minus pre-
test group mean) divided by (pre-test group mean)]× 100), the
changes between sequential CAPS scores were measured and how
strong the relationship was between them was calculated. In this
last case, a value of 0.01–0.09 is a small effect, a value of 0.10–0.25
is a medium effect and a value of over 0.25 represents a large ES.
Similar calculations were done to assess the long-term efficacy of
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the treatment modality by considering the difference pre and post
(at 3 months after treatment) of the CAPS Total Severity Scores
for each subject (matched pairs).
RESULTS
For the 98 subjects participating in the study, Table 1 shows the
two-way table with measures of association for the CAPS Total
Severity Scores pre- and 1 week post-treatment divided into each
category (Minimal, Mild, Moderate, Severe, and Extreme) and
their relative percentage. The rows represent the pre-treatment
classification, the columns represent the 1 week post-treatment
classification. Figure 1 gives a graphical representation of the
same percentages, whereas Figure 2 shows the scatter plot of the
1 week post-treatment CAPS Total Severity Scores versus the pre-
treatment CAPS Total Severity Scores for each subject, color coded
for the different categories pre-treatment. The change in CAPS
Total Severity Scores had aχ2 (16,N = 98)= 132.7399, p< 0.001,
φ= 0.5819.
Table 2 shows, for the five pre-treatment categories of the CAPS
Total Severity Scores and for the overall population, the mean and
its 95% confidence interval (95% CI), the standard error, and the
SD of the pre, 1 week post, and difference distributions, as well as
the two-tailed repeated measures pre–post t -Test, its significance
p, and the three calculated ES (Point-biserial r, Cohen’s d, and
Hedge’s g ) based on mean comparison and their 95% CI.
DISCUSSION
As indicated in Table 1 and Figure 1, prior to treatment, 75 sub-
jects (representing 76.5% of the sample) were classified in the two
most severe categories of PTSD: of these, 41 subjects (41.8%) were
classified in the Extreme category, and 34 subjects (34.7%) were
classified in the Severe category; 17 subjects (17.4%) were classi-
fied in the Moderate category; 4 subjects (4.1%) were classified
in the Mild category, and only 2 subjects (2.0%) were classi-
fied in the Minimal category. One week after treatment, only
48 subjects (49.0%) remained in the two most severe categories
of PTSD: this represents a 36% improvement of the symptoms.
The improvement effect is even more remarkable when consider-
ing the Extreme category: 41 subjects pre-treatment vs. 15 1 week
post-treatment, a success rate in decreasing the symptoms classifi-
cation of 63.4%. Furthermore, the improvement allowed subjects
to be classified not only in the Severe category (the immediate
lower category) but also in the Moderate and Mild categories:
16 subjects (39.0%) were reclassified as Severe sufferers post-
treatment, 8 subjects (19.5%) as Moderate, and 2 subjects (4.9%)
as Mild. Similar trend was found for subjects originally classi-
fied in the Severe category [of those 34 subjects, 15 (44.1%)
remained in the Severe category, 17 (50%) became Moderate,
and 1 (2.9%) became Mild] and in the Moderate category [of
those 17 subjects, 8 (47.1%) remained in the Moderate category,
7 (41.2%) became Mild and 1 (5.9%) became Minimal]. In both
Table 1 |Two-way table with measures of association for the CAPSTotal Severity Scores pre and 1 week post-treatment divided into each
category (Minimal, Mild, Moderate, Severe, and Extreme), and their relative percentage.
Severity category pre Severity category post
Minimal Mild Moderate Severe Extreme Total
Minimal 0–19 2 0 0 0 0 2
100.00 0.00 0.00 0.00 0.00 100.00
66.67 0.00 0.00 0.00 0.00 2.04
Mild 20–39 0 4 0 0 0 4
0.00 100.00 0.00 0.00 0.00 100.00
0.00 28.57 0.00 0.00 0.00 4.08
Moderate 40–59 1 7 8 1 0 17
5.88 41.18 47.06 5.88 0.00 100.00
33.33 50.00 24.24 3.12 0.00 17.35
Severe 60–79 0 1 17 15 1 34
0.00 2.94 50.00 44.12 2.94 100.00
0.00 7.14 51.52 46.88 6.25 34.69
Extreme 80–136 0 2 8 16 15 41
0.00 4.88 19.51 39.02 36.59 100
0.00 14.29 24.24 50 93.75 41.84
Total 3 14 33 32 16 98
3.06 14.29 33.67 32.65 16.33 100.00
100.00 100.00 100.00 100.00 100.00 100.00
χ2 (16, N=98)=132.7399, p< 0.001, φ=0.5819.
The rows represent the pre-treatment classification, the columns the 1 week post-treatment classification.
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FIGURE 1 | Percentage of CAPS total severity scores pre and 1 week post-treatment for each category (Minimal, Mild, Moderate, Severe, and Extreme).
cases, only 1 subject (2.9% for the Severe category and 5.9% for
the Moderate category respectively) had worse symptoms clas-
sification 1 week post-treatment. The subjects classified in the
Mild and Minimal categories maintained the same classification
1 week post-treatment. Furthermore, the overall results showed
in Table 1 revealed strong statistical (p= 0.001< 0.05) and sub-
stantive (φ= 0.58> 0.5) significance (a φ >0.5 is considered a
strong relationship). Considering Figure 2, the same information
can be extrapolated: for example, the two subjects in the minimal
category pre-treatment (with pre-treatment score <20 – x axis)
stayed in the same category 1 week post-treatment (their y value
is still <20); similarly, for the 34 subjects in the Severe category
(pre-treatment score between 60 and 80), 1 had an increase in
score (higher than 80), 15 stayed in the same range, 17 moved
to the immediately lower range (40–60), and 1 “jumped” two
categories lower (20–40). When considering how much change
each subject had (Figure 3), as well as on average by categories, it
is evident that the “worse” the original classification, the greater
the change (a negative change indicates improvement, a positive
change indicates a worsening of the condition). Furthermore, with
the exclusion of two subjects that had a worsening of the clas-
sification of their symptoms after treatment (one in the Severe
and one in the Moderate category as Reported in Table 1), most
of the subjects, even if they did not change category, showed an
improvement: only four subjects, i.e., 4.1% (one in the Mild, two
in the Moderate, and one in the Severe), had a clear worsening
of their CAPS scores. Furthermore, these changes are statisti-
cally significant for the Moderate, Severe and Extreme categories
(p< 0.05 as indicated in Table 2). They are also substantively sig-
nificant as indicated by the ES reported in Table 2 as well. For the
Extreme category not only do all three ES indicate a large effect
(r > 0.25, and d and g > 0.8), with their 95% CI also demonstrat-
ing this. For the Severe category the same applies except for the
lower limit of the Hedge’s g CI. For the Moderately category, the
ES indicate a large effect, but not when considering their 95%
CI. The Mild and Minimal categories have too few subjects that
their results are not statistically significant (p> 0.05), although
FIGURE 2 | Scatter plot of 1 week post- vs. pre-treatment scores color
coded for the different categories.
for the Mild category, the ES is still large (but not when consider-
ing their 95% CI). When considering all the subjects together, the
changes are statistically significant (p< 0.001), but only the point-
biserial r indicates a substantive significance (r = 0.35> 0.25)
almost with 95% confidence (lower limit= 0.22, thus medium
effect), whereas the Cohen’s d and Hedge’s g indicate a moderate
ES (0.73< 0.8).
One more consideration must be made regarding the sub-
jects in our study: they had a mean pre-treatment CAPS Total
Severity Score equal to 210% of that reported in the paroxe-
tine therapy (23) study (73.1 vs. 34.8) and to 308.4% of that
reported in the cognitive behavioral study (24) (73.1 vs. 23.7).
These higher scores represented greater levels of PTSD and yet
the outcomes of our treatment strategies have been successful and
associated with a greater statistical and substantive significance
than we hypothesized. Unfortunately, only 14 subjects returned
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Table 2 | For the different pre-treatment categories of the CAPSTotal Severity Scores and for the overall population: mean and its 95%
confidence interval (CI), standard error, and standard deviation of the pre, 1 week post, and difference distributions, as well as the two-tailed
repeated measures pre–post t -Test, its significance p, and the three calculated effect size (Point-biserial r, Cohen’s d, and Hedge’s g) based on
mean comparison.
Mean (95% CI) SE SD t P Point-biserial
r (95% CI)
Cohen’s
d (95% CI)
Hedges’s
g (95% CI)
Minimal (2 sbj) Pre 15.00 (−35.82 65.82) 4.00 5.66 0.67 0.626 −0.32 (−0.86 0.74) −0.49 (−2.44 1.58) −0.27 (−1.38 0.89)
1 week Post 17.00 (4.29 29.71) 1.00 1.41
Diff 2.00 (−40.12 36.12) 3.00 4.42
Mild (4 sbj) Pre 31.00 (21.81 40.19) 2.89 5.77 1.68 0.192 0.51 (−0.28 0.82) 1.04 (−0.50 2.50) 0.90 (−0.43 2.17)
1 week Post 25.50 (17.87 33.13) 2.40 4.80
Diff 5.50 (−4.93 15.93) 3.28 6.56
Moderate (17 sbj) Pre 52.41 (50.06 54.77) 1.11 4.58 2.38 <0.05 0.40 (0.07 0.62) 0.84 (0.13 1.53) 0.82 (0.13 1.50)
1 week Post 44.00 (37.09 50.91) 3.26 13.44
Diff 8.41 (0.93 15.92) 3.54 14.60
Severe (34 sbj) Pre 70.65 (68.65 72.64) 0.98 5.71 7.05 <0.001 0.56 (0.38 0.69) 1.33 (0.80 1.85) 1.32 (0.79 1.83)
1 week Post 56.88 (52.19 61.58) 2.31 13.45
Diff 13.76 (9.79 17.74) 1.95 11.38
Extreme (41 sbj) Pre 90.73 (88.36 93.10) 1.17 7.51 7.87 <0.001 0.60 (0.44 0.70) 1.47 (0.97 1.95) 1.45 (0.97 1.93)
1 week Post 71.20 (65.74 76.65) 2.70 17.27
Diff 19.54 (14.56 24.51) 2.46 15.77
Total (98 sbj) Pre 73.13 (69.17 77.09) 2.00 19.76 9.98 <0.001 0.35 (0.22 0.46) 0.73 (0.44 1.02) 0.73 (0.44 1.02)
1 week Post 58.54 (54.52 62.56) 2.02 20.03
Diff 14.45 (11.53 17.37) 1.47 14.49
In bold, the significant values.
for the 3-month follow up CAPS evaluation: after treatment, most
subjects were able to return to a higher quality of normal life
with increased activity to become productive members of soci-
ety that did not feel the need to be assessed again. Traveling time
and costs could have also played a role in this decision not to
return for the follow-up evaluation as the subjects were sent to
us from around the United States. Although the significance of
the 3-month post-treatment results is not as strong as the results
obtained at the 1-week post-treatment, there was still a mean
improvement (53.14 vs. 58.54 after 1 week) pointing toward a
possible continuing improvement of the PTSD symptoms. When
considering the overall results obtained in this study, the greater
improvements found with subjects in the Extreme and Severe
categories are in line with what we usually find in our clinical
experience with athletes suffering from CTE and mTBI: the worse
the symptoms, the greater the response to the customized novel
brain and VR treatment modality used in this study. This appears
to follow the Pareto Principle or 80–20 curve, for which there is a
lot of improvement for the same amount of effort if the margin for
improvement is large. In this particular situation, subjects in the
Extreme and Severe categories had so many issues and symptoms
that treatment had larger effects. This also confirms what we see
in our clinical experience.
CONCLUSION
This investigation has analyzed the use of a novel brain and
VR treatment modality in PTSD patients who have suffered
combat-related traumatic brain injuries immediately and over
time after treatment. In general, we obtained both strong statistical
and substantive significant outcomes. The treatment of this disor-
der as a physical injury with brain and vestibular non-invasive and
non-pharmaceutical applications has never been reported. Fur-
ther, a successful 2-week treatment period may be associated with
significant savings of cost, time, and disability when compared to
longer therapy programs. There may be a stigma associated with
having a neuropsychiatric diagnosis of PTSD that might be less-
ened if a physicality of etiology similar to that commonly accepted
in mTBI is embraced. Our investigation has the promise of devel-
opment of superior outcomes of treatments in this area that will
benefit a global society.
STRENGTHS ANDWEAKNESSES OF THE STUDY
Clinical practice guidelines are dependent upon quality inves-
tigations that ultimately drive physician applications. We are
embracing an opportunity to be involved in change and best
practice development associated with the positive outcome of
our study. The observed clinical results of our treatments might
change the direction of therapy sponsored by government and
private agencies. We may have a limitation of our study spe-
cific to the gathering of long-term post-treatment CAPS scores
because of the nation wide distribution of our sample popula-
tion as well as life style changes associated with decreased PTSD
suffering. We have had difficulty having subjects return to our
facility for retesting and we are designing a better method of
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FIGURE 3 | Box plots and scatter plots of pre and 1 week post-treatment
for the different pre-treatment categories of the CAPS total severity
scores and for the overall population, obtained from the results of
Table 2. When considering the 3 months follow up, 84 subjects dropped out
of the study. For the 14 that underwent the CAPS testing, the mean CAPS
Total Severity Score was 53.14.
obtaining follow-up testing for future investigations. We utilized
only one licensed psychologist trained in administration of the
CAPS in order to decrease any inter-examiner differences. We are
considering having multiple psychologists administer the CAPS
testing at different locations throughout the country and con-
trolling for inter-examiner differences in the future, so to facil-
itate the return of subjects for long-term follow-up evaluation.
We are also looking into the inclusion of other instruments to
measure subject satisfaction and depression as another possi-
ble measure of outcome measure. This study did not include
any female subjects. We are aware of many female military vet-
erans who have suffered blast injuries and resultant PTSD but
no females were assigned to us by the referring agencies. Future
research is needed to verify if similar outcomes can be obtained
with women.
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